The answer (in the UK at least) is yes when taken by patients after their first heart attack.
Using cost effectiveness mathematical models for cost for life years gained and cost per death avoided, Lovacor (aka Omacor) (omega-3-acid ethyl esters) when taken as a standard post-heart attack prevention treatment seems warranted both on the basis of the efficacy and the cost-effectiveness at 4 years and over a lifetime.
The benefits offered by Lovacor are in addition to the benefits from taking statins and other prophylactic treatments.
John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.